Cyramza ® (ramucirumab)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information: Cyramza Summary of Product Characteristics (SmPC)

Was Cyramza® (ramucirumab) efficacious as single-agent following paclitaxel discontinuation in RAINBOW?

Patients who discontinued paclitaxel had a median overall survival (OS) of 15.7 months and progression-free survival (PFS) of 8.5 months.


Patients Who Discontinued Treatment with Paclitaxel and Continued Treatment with Ramucirumab

31 of 330 patients discontinued paclitaxel due to toxicity and received ramucirumab alone. In the placebo group, 11 patients discontinued paclitaxel and continued on placebo alone.1,2

Please interpret the following results with caution due to the small number of patients. The efficacy outcomes for these patients are summarized inEfficacy Outcomes for Patients who Discontinued Treatment with Paclitaxel Due to Adverse Events vs patients who continued on the planned course .

Efficacy Outcomes for Patients who Discontinued Treatment with Paclitaxel Due to Adverse Events vs patients who continued on the planned course1 


Ramucirumab + Paclitaxel


Placebo + Paclitaxel


Median OS, months (95% CI)

15.7 (12.6-NA)

10.9 (5.7-14.9)

1-year OS (95% CI)

73.3% (53.5-85.7)

45.5% (16.7-70.7)

Median PFS, months (95% CI)

8.5 (5.7-9.7)

5.6 (2.6-7.8)

6-month PFS (95% CI)

64.2% (44.7-78.4)

36.4% (11.2-62.7)

 Abbreviations: NA = not available; OS = overall survival; PFS = progression-free survival.

The number of additional cycles of ramucirumab that patients who discontinued paclitaxel received are summarized in  Additional Cycles of Single-Agent Ramucirumab after Discontinuation of Paclitaxel.

 Additional Cycles of Single-Agent Ramucirumab after Discontinuation of Paclitaxel1

Additional Cycles

Ramucirumab + Paclitaxel (n=31)

Number of patients (%)

Additional 1 cycle

10 (32.3)

Additional 2 cycles

8 (25.8)

Additional 3 cycles

4 (12.9)

Additional 4 cycles

2 (6.5)

Additional 6 cycles

2 (6.5)

Additional 8 cycles

1 (3.2)

Additional 9 cycles

2 (6.5)

Additional 11 cycles

1 (3.2)

Additional 14 cycles

1 (3.2)

Rainbow Study Design

The RAINBOW trial was a phase 3, multicenter, randomized, double-blind, placebo-controlled trial in patients with metastatic or locally advanced nonresectable gastric or gastroesophageal junction (GEJ) adenocarcinoma. 

Patients had to have disease progression during or within 4 months after the last dose of first-line platinum plus fluoropyrimidine combination chemotherapy with or without an anthracycline.

All patients had an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1.

Patients were randomly assigned in a 1:1 ratio, stratified by

  • region,
  • measurable vs nonmeasurable disease, and
  • time-to-progression (TTP) on first-line therapy

to receive either

  • ramucirumab (8 mg/kg days 1 and 15) plus paclitaxel (80 mg/m2 days 1, 8, and 15) (n=330) or
  • placebo (days 1 and 15) plus paclitaxel (80 mg/m2 days 1, 8, and 15) (n=335)

of a 28-day cycle until disease progression, unacceptable toxicity, withdrawal, or death.2


1Data on file, Eli Lilly and Company and/or one of its subsidiaries.

2Wilke H, Muro K, Van Cutsem E, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15(11):1224-1235.

Date of Last Review: September 15, 2021

Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at

Available Mon - Fri, 10am - 4pm, excluding Bank Holidays

Or you can

Chat with Us

Click to Chat is Offline

If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a request